Biogen Idec Announces Management Change



    CAMBRIDGE, MASS., June 29 /CNW/ - Biogen Idec (NASDAQ:   BIIB) announced
today that Peter Kellogg, Executive Vice President, Finance & Chief Financial
Officer (CFO) will leave the organization to become CFO at Merck & Co., Inc.

    "I want to thank Peter for his seven years of distinguished service to
the organization," stated James C. Mullen, Biogen Idec's President and Chief
Executive Officer. "Peter is a world-class financial executive who helped
Biogen Idec grow our core therapeutic areas, execute several significant
deals, and expand our global footprint. We wish him all the best with his new
assignment at Merck."

    Mr. Kellogg will leave Biogen Idec on August 10. The Company will
announce its plans regarding the CFO position over the next several weeks.

    About Biogen Idec

    Biogen Idec creates new standards of care in therapeutic areas with high
unmet medical needs. Founded in 1978, Biogen Idec is a global leader in the
discovery, development, manufacturing, and commercialization of innovative
therapies. Patients in more than 90 countries benefit from Biogen Idec's
significant products that address diseases such as lymphoma, multiple
sclerosis, and rheumatoid arthritis. For product labeling, press releases and
additional information about the company, please visit www.biogenidec.com.




For further information:

For further information: Biogen Idec Media Contact: Tim Hunt,
617-914-6524 Vice President Public Affairs or Investment Community Contact:
Elizabeth Woo, 617-679-2812 Vice President Investor Relations

Organization Profile

BIOGEN IDEC

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890